Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark.

Abstract

OBJECTIVES:

To evaluate the cost-effectiveness of treating patients with acute coronary syndromes (ACS) for 12 months with ticagrelor compared with generic clopidogrel in Sweden and Denmark.

DESIGN:

Decision-analytic model to estimate lifetime costs, life-expectancy, and quality-adjusted life years (QALYs) with ticagrelor and clopidogrel. Event rates, healthcare resource use, and health-related quality of life during 12 months of therapy were estimated from the PLATelet inhibition and patient Outcomes (PLATO) trial. Beyond 12 months, quality-adjusted survival and costs were estimated conditional on events occurring during the 12 months of therapy. When available, country-specific data were employed in the analysis. Incremental cost-effectiveness ratios are presented from a healthcare perspective and a broader societal perspective including costs falling outside the healthcare sector in 2010 local currency.

RESULTS:

The cost per QALY with ticagrelor compared with generic clopidogrel was SEK 25 022 and DKK 26 892 for Sweden and Denmark, respectively, from a healthcare perspective. The cost per QALY from a broader societal perspective was SEK 24 290 and DKK 25 051 for Sweden and Denmark, respectively.

CONCLUSION:

The cost per QALY of treating ACS-patients with ticagrelor compared with generic clopidogrel is below the conventional thresholds of cost-effectiveness in Sweden and Denmark.

• Authors: Martin Henriksson, Elisabet Nikolic, Audun Ohna, Lars Wallentin, Magnus Janzon
• Journal: Scandinavian cardiovascular journal : SCJ (Scand Cardiovasc J) Vol. 48 Issue 3 Pg. 138-47 (Jun 2014) ISSN: 1651-2006 [Electronic] England
• PMID: 24650118 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Purinergic P2Y Receptor Antagonists
• Clopidogrel
• Ticagrelor
• Adenosine
• Ticlopidine

Topics

• Acute Coronary Syndrome (drug therapy)
• Adenosine (analogs & derivatives, economics, therapeutic use)
• Clopidogrel
• Cost-Benefit Analysis
• Denmark
• Humans
• Purinergic P2Y Receptor Antagonists (economics, therapeutic use)
• Sweden
• Ticagrelor
• Ticlopidine (analogs & derivatives, economics, therapeutic use)